Doxorubicin–Trabectedin with Trabectedin Maintenance in Leiomyosarcoma,The New England Journal of Medicine

当前位置： X-MOL 学术 › N. Engl. J. Med. › 论文详情

Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)

Doxorubicin–Trabectedin with Trabectedin Maintenance in Leiomyosarcoma
The New England Journal of Medicine ( IF 96.2 ) Pub Date : 2024-09-05 , DOI: 10.1056/nejmoa2403394
Patricia Pautier ₁ , Antoine Italiano ₁ , Sophie Piperno-Neumann ₁ , Christine Chevreau ₁ , Nicolas Penel ₁ , Nelly Firmin ₁ , Pascaline Boudou-Rouquette ₁ , François Bertucci ₁ , Valérie Lebrun-Ly ₁ , Isabelle Ray-Coquard ₁ , Elsa Kalbacher ₁ , Emmanuelle Bompas ₁ , Olivier Collard ₁ , Nicolas Isambert ₁ , Cécile Guillemet ₁ , Maria Rios ₁ , Axel Le Cesne ₁ , Corinne Balleyguier ₁ , Baptiste Archambaud ₁ , Florence Duffaud ₁ ,

Affiliation

From the Departments of Medical Oncology (P.P., A.L.C.), Radiology (C.B.), and Biostatistics and Epidemiology (B.A.), Institut Gustave-Roussy, and Oncostat, INSERM Unité 1018, Labeled Ligue Contre le Cancer (B.A.), Villejuif, the Department of Medical Oncology, Institut Bergonié, and the Faculty of Medicine, University of Bordeaux, Bordeaux (A.I.), the Department of Medical Oncology, Institut Curie (S.P.-N.), and the Department of Medical Oncology, Hôpital Cochin-Port Royal (P.B.-R.), Paris, the Department of Medical Oncology, Institut Universitaire du Cancer de Toulouse-Oncopole, Toulouse (C.C.), Lille University, and the Department of Medical Oncology, Centre Oscar Lambret, Lille (N.P.), the Department of Medical Oncology, Institut Régional du Cancer, INSERM Unité 1194, Institut de Recherche en Cancérologie de Montpellier, and the University of Montpellier, Montpellier (N.F.), the Department of Medical Oncology, Institut Paoli-Calmettes (F.B.), the Department of Medical Oncology, La Timone University Hospital (F.D.), and Aix-Marseille Université (F.B., F.D.), Marseille, the Department of Medical Oncology, Centre Hospitalo-Universitaire Dupuytren, Limoges (V.L.-L.), the Department of Medical Oncology, Centre Léon Bérard, and University Claude-Bernard Lyon 1, Lyon (I.R.-C.), the Department of Medical Oncology, Centre Hospitalier Universitaire de Besançon-Hôpital Jean-Minjoz, Besançon (E.K.), Institut de Cancérologie de l'Ouest, Angers-Nantes (E.B.), Institut de Cancérologie de la Loire, Saint-Priest-en-Jarez (O.C.), Centre Georges-François Leclerc, Dijon (N.I.), the Department of Medical Oncology, Centre Paul Papin, Rouen (C.G.), and Institut de Cancérologie de Lorraine, Vandoeuvre-lès-Nancy (M.R.) - all in France.

The addition of trabectedin to doxorubicin, followed by trabectedin maintenance, may have superior efficacy to doxorubicin alone as first-line treatment in patients with advanced leiomyosarcoma.We ...

中文翻译：